Roche Launches uPath PD-L1 (SP263) Automated Digital Pathology Algorithm to Speed Up NSCLC Diagnosis

 Roche Launches uPath PD-L1 (SP263) Automated Digital Pathology Algorithm to Speed Up NSCLC Diagnosis

Roche Launches uPath PD-L1 (SP263) Automated Digital Pathology Algorithm to Speed Up NSCLC Diagnosis

Shots:

  • uPath PD-L1 (SP263) image analysis utilizes automated pre-computing and one-click scoring to enable quicker and accurate detection and measurement of tumor cell staining positivity
  • All algorithms in the suite for uPath software will provide image analysis of VENTANA DP 200 scanned slide images stained with a Roche tissue assay, allowing pathologists to quickly determine whether tumors are PD-L1 biomarker positive, highlighting positively & negatively stained tumor cells with a clear visual overlay for easy reference
  • This launch of uPath PD-L1 (SP263) image analysis for NSCLC follows the release of the Roche’s uPath enterprise software in Jan’2019. When used with the CE-marked VENTANA PD-L1 (SP263) Assay, uPath is indicated as an aid to identif patients for treatment with therapies with the ≥ 50% PD-L1 TC positivity cutoff in accordance with the approved therapeutic product labeling

Click here to read full press release/ article | Ref: Roche | Image: Roche

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post